Int. j. adv. multidisc. res. stud. 2024; 4(6):2473-2478

Received: 11-11-2024
Accepted: 21-12-2024

International Journal of Advanced Multidisciplinary Research and Studies

ISSN: 2583-049X

Enhancing Innate Immune Responses in Viral Infections: Recent Advances

[1] Opeoluwa Oluwanifemi Akomolafe, [2] Irene Sagay-Omonogor, [3] Tolulope Bolarinwa

[1] Independent Researcher, UK
[2] Independent Researcher, Maryland, MD, USA
[3] Indepenent Researcher, Indiana, USA

DOI: https://doi.org/10.62225/2583049X.2024.4.6.4483
Corresponding Author: **Tolulope Bolarinwa**

Abstract

Enhancing innate immune responses against viral infections is a burgeoning area of research aimed at bolstering the body's initial defense mechanisms. This review explores recent advances and challenges in leveraging innate immunity, focusing on immunomodulatory drugs, genetic and epigenetic modifications, and novel vaccination strategies. Immunomodulatory agents, including Toll-like receptor agonists and interferon-stimulating agents, aim to amplify innate immune signaling pathways crucial for antiviral defense. Genetic editing technologies, such as CRISPR-Cas9, offer precision in enhancing immune responses by targeting key regulatory genes. Epigenetic modifications present a promising avenue for modulating immune cell function without altering DNA sequences. Additionally, innovative vaccination approaches that stimulate innate immune pathways alongside adaptive immunity can potentially improve vaccine efficacy against viral pathogens. Challenges such as balancing immune activation and regulation, addressing safety concerns, and overcoming viral evasion strategies are discussed. Future directions include integrating emerging technologies, optimizing translational research efforts, and advancing clinical applications to harness the full potential of innate immunity in combating viral infections.

Keywords: Innate Immunity, Viral Infections, Immunomodulatory Drugs, Genetic Modifications, Vaccination Strategies, Immune Response Integration

1. Introduction

The immune system is a complex network of cells, tissues, and organs that work in concert to defend the body against harmful pathogens, including viruses. A critical component of this defense mechanism is the innate immune system, which serves as the first line of defense against infections. Unlike the adaptive immune system, which requires time to develop a specific response to an invading pathogen, the innate immune system responds immediately, employing various mechanisms to recognize and eliminate potential threats. This rapid response is crucial for controlling viral infections during the initial stages, buying time for the more specialized adaptive immune response to be mobilized (Wicherska-Pawłowska, Wróbel, & Rybka, 2021) [29].

The innate immune response is primarily mediated by pattern recognition receptors (PRRs) that detect pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs). Key PRRs include Toll-like receptors (TLRs), RIG-I-like receptors (RLRs), and NOD-like receptors (NLRs), each recognizing distinct molecular signatures associated with viral infections. Activation of these receptors triggers signaling cascades that produce interferons and other cytokines, which play pivotal roles in antiviral defense. Interferons, particularly type I interferons (IFN-α and IFN-β), are essential in establishing an antiviral state within infected and neighboring cells, inhibiting viral replication and spreading (Li & Wu, 2021; Tanaka & Heil, 2021) [16, 26].

The importance of the innate immune system in viral infections cannot be overstated. It provides an immediate response to viral entry, limiting viral replication and spread until the adaptive immune response can be engaged. This initial control is vital in highly pathogenic viruses, where rapid viral replication and dissemination can lead to severe disease and high mortality. Moreover, the innate immune response shapes the adaptive immune response, influencing the nature and magnitude of the ensuing immune memory. Effective innate immune activation can enhance the effectiveness of vaccines and improve long-term immunity against viral pathogens (McDaniel, Meibers, & Pasare, 2021) [17].

In recent years, significant advances have beenmade in understanding and manipulating the innate immune response to enhance antiviral defenses. One of the key areas of progress is the development of immunomodulatory drugs and small molecules that can boost innate immune functions. These agents enhance the body's natural ability to detect and respond to viral infections, providing a broad-spectrum approach to antiviral therapy. For instance, synthetic agonists of TLRs have shown promise in preclinical studies, demonstrating the potential to enhance the production of interferons and other cytokines that are crucial for antiviral defense (Sun & Barreiro, 2020) [24]. Another exciting avenue of research involves genetic and epigenetic modifications to enhance innate immunity. Advances in gene editing technologies, such as CRISPR-Cas9, have enabled precise modifications of genes involved in innate immune responses. These modifications can enhance the expression and function of key immune proteins, potentially leading to improved control of viral infections. Additionally, epigenetic modifications, which do not alter the DNA sequence but affect gene expression, offer a novel strategy to boost innate immune functions. For example, modulating the epigenetic landscape of immune cells can enhance their responsiveness to viral infections, providing a new layer of immune regulation (Sharma *et al*., 2021; Tien, Lu, Lin, & Tsai, 2023) [23, 27].

Vaccination strategies that target innate immunity represent another promising area of research. Traditionally, vaccines have focused on eliciting strong adaptive immune responses, particularly the production of neutralizing antibodies. However, recent studies have highlighted the importance of innate immune activation in shaping the overall immune response to vaccination. Adjuvants, substances added to vaccines to enhance their immunogenicity, are increasingly designed to activate innate immune pathways. By stimulating PRRs and other innate immune receptors, these adjuvants can enhance the initial immune response to the vaccine, leading to more robust and long-lasting protection against viral infections (Sepulveda-Crespo, Resino, & Martinez, 2020) [22].

Despite these advances, there are still significant challenges and limitations in enhancing innate immune responses. One of the primary concerns is the potential for overstimulation of the immune system, which can lead to excessive inflammation and tissue damage. Balancing the activation of innate immunity to achieve effective antiviral responses without causing harmful side effects is a delicate task. Furthermore, viruses have evolved various mechanisms to evade and subvert the innate immune system, posing additional challenges for developing effective therapies. Understanding these viral evasion strategies is critical for designing interventions to overcome these obstacles and restore effective immune control.

2. Mechanisms of Innate Immune Response Activation

The innate immune response is the body's first defense against invading pathogens, including viruses. This rapid and non-specific defense mechanism is crucial for controlling infections in their early stages. The activation of innate immunity is mediated by a network of receptors and signalingpathways that detect and respond to pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs). Central to this process are pattern recognition receptors (PRRs), which initiate the signaling cascades leading to the production of cytokines and interferons, key mediators of the immune response(Diaz-Arévalo & Zeng, 2020; Galli, Vacher, Ryffel, Blanco, & Legembre, 2022) [6, 9].

Pattern recognition receptors (PRRs) are essential for detecting viral components and initiating innate immune responses. These receptors are expressed on various immune cells, including macrophages, dendritic cells, epithelial cells, and non-immune cells. PRRs recognize conserved molecular structures in pathogens, such as viral RNA or DNA, and initiate a rapid immune response. Among the most studied PRRs are Toll-like receptors (TLRs), RIG-I-like receptors (RLRs), and NOD-like receptors (NLRs)(Díaz-Dinamarca *et al*., 2022) [7].

TLRs are a family of membrane-bound receptors that recognize a wide range of PAMPs. For example, TLR3 detects double-stranded RNA, a replication intermediate of many viruses, while TLR7 and TLR8 recognize single-stranded RNA. Upon realizing their ligands, TLRs undergo conformational changes that lead to the recruitment of adaptor proteins, such as MyD88 and TRIF. This recruitment triggers downstream signaling pathways, activating transcription factors like NF-κB and interferon regulatory factors (IRFs), which drive the expression of pro-inflammatory cytokines and type I interferons (Behzadi, García-Perdomo, & Karpiński, 2021; Vercammen, Staal, & Beyaert, 2008) [3, 28].

RLRs, including RIG-I and MDA5, are cytoplasmic sensors of viral RNA. RIG-I recognizes short double-stranded RNA with a 5’ triphosphate end, commonly produced by RNA viruses, while MDA5 detects long double-stranded RNA. Upon binding to their respective ligands, RLRs undergo conformational changes that facilitate their interaction with the mitochondrial antiviral-signaling protein (MAVS) (Rehwinkel & Gack, 2020) [21]. This interaction triggers a signaling cascade that activates IRF3 and IRF7, producing type I interferons and other cytokines essential for antiviral defense.NLRs, such as NOD2 and NLRP3, are intracellular sensors that detect bacterial and viral components as well as endogenous danger signals. NLRP3, in particular, is a key component of the inflammasome, a multiprotein complex that activates caspase-1, leading to the maturation and secretion of pro-inflammatory cytokines like IL-1β and IL-18. These cytokines play crucial roles in amplifying the immune response and recruiting additional immune cells to the site of infection (Hamrashdi & Brady, 2022) [11].

The signaling pathways activated by PRRs are critical for producing cytokines and interferons, which are essential mediators of the innate immune response. One of the central pathways involved in PRR signaling is the NF-κB pathway. NF-κB is a transcription factor normally held inactive in the cytoplasm by inhibitor proteins called IκBs. Upon activation by PRR signaling, IκBs are phosphorylated and degraded, allowing NF-κB to translocate to the nucleus. In the nucleus, NF-κB binds to the promoters of various genes encoding pro-inflammatory cytokines, chemokines, and other immune-related molecules, initiating their transcription (Barnabei, Laplantine, Mbongo, Rieux-Laucat, & Weil, 2021; Tan, Zhang, & Tee, 2022) [2, 25].

Interferon regulatory factors (IRFs) are another group of transcription factors that play crucial roles in antiviral responses. IRF3 and IRF7, in particular, are pivotal in producing type I interferons. Upon activation by PRR signaling, IRF3 and IRF7 are phosphorylated and

translocated to the nucleus, where they induce the expression of interferon-stimulated genes (ISGs). ISGs encode proteins with antiviral activities, such as protein kinase R (PKR), which inhibits viral protein synthesis, and Mx proteins, which interfere with viral replication and assembly (Goraya *et al*., 2020) [10].

Cytokines and interferons are the key effector molecules of the innate immune response. Cytokines, such as IL-1β, IL-6, and TNF-α, mediate inflammation and recruit immune cells to the site of infection. These cytokines enhance the phagocytic and microbicidal activities of macrophages and neutrophils, facilitating the clearance of infected cells. Additionally, cytokines promote the activation and maturation of dendritic cells, which are critical for initiating adaptive immune responses (Xu, Cheng, Shang, & Yang, 2022) [30].

Interferons, particularly type I interferons (IFN-α and IFN-β), are essential for establishing an antiviral state in infected and neighboring cells. Type I interferons bind to their receptors on the cell surface, activating the JAK-STAT signaling pathway. This pathway leads to the transcription of ISGs, which encode proteins that inhibit various stages of viral replication. For example, ISG15 and ubiquitin-like proteins modify viral and host proteins, interfering with viral replication and assembly. Furthermore, type I interferons enhance the antigen presentation capabilities of dendritic cells and the cytotoxic activities of natural killer (NK) cells and cytotoxic T lymphocytes (CTLs), bridging the innate and adaptive immune responses (Abakushina *et al*., 2021; Lapenta, Gabriele, & Santini, 2020) [1, 15].

3. Recent Advances in Enhancing Innate Immunity

Enhancing innate immunity represents a promising strategy in the fight against viral infections. While the innate immune system offers a rapid and broad response to pathogens, leveraging recent scientific advancements can further amplify its effectiveness. These advancements fall into three categories: Immunomodulatory drugs and small molecules, genetic and epigenetic modifications, and innovative vaccination strategies targeting innate immunity.

3.1 Immunomodulatory Drugs and Small Molecules

The development of immunomodulatory drugs and small molecules aims to enhance the innate immune response by boosting the body's natural defenses. These agents target various immune system components to improve their ability to recognize and combat viral pathogens. One prominent approach involves the use of Toll-like receptor (TLR) agonists. TLRs are a pattern recognition receptor (PRR) type that plays a critical role in detecting viral components and initiating immune responses. For example, synthetic TLR7 and TLR8 agonists have shown promise in stimulating the production of type I interferons and other cytokines, thereby enhancing antiviral immunity (Davis, Ferreira, Paige, Gedye, & Boyle, 2020; Federico *et al*., 2020) [5, 8].

Another class of immunomodulatory agents includes RIG-I-like receptor (RLR) agonists. RLRs, such as RIG-I and MDA5, detect viral RNA in the cytoplasm and activate downstream signaling pathways that produce interferons and pro-inflammatory cytokines. Small molecules that activate RLRs can potentiate these antiviral responses, providing a rapid defense against a broad spectrum of viruses. Additionally, interferon-stimulating agents (ISAs) are being developed to boost the production and activity of interferons, enhancing the antiviral state within infected and neighboring cells (Wicherska-Pawłowska *et al*., 2021) [29].

3.2 Genetic and Epigenetic Modifications

Advances in genetic and epigenetic technologies have opened new avenues for enhancing innate immunity. Gene editing tools like CRISPR-Cas9 allow for precise modifications of genes involved in immune responses, potentially improving their expression and function. For instance, editing genes that encode PRRs or their signaling components can increase the sensitivity and responsiveness of the innate immune system to viral infections. This can lead to a more robust production of antiviral cytokines and interferons, improving the control of viral replication (Khandia *et al*., 2022; Zhang, Liu, & Liu, 2024) [14, 31].

Epigenetic modifications offer another layer of regulation that can be harnessed to enhance innate immunity. Epigenetic changes, such as DNA methylation and histone modification, influence gene expression without altering the DNA sequence. Modulating these epigenetic marks can enhance gene expression in innate immune responses. For example, demethylation of promoter regions in genes encoding interferons and other cytokines can increase transcription and heightened antiviral responses. Moreover, drugs that modify the epigenetic landscape, such as histone deacetylase inhibitors (HDACi), can enhance the antiviral functions of immune cells by promoting the expression of key immune genes (Hogg, Beavis, Dawson, & Johnstone, 2020) [12].

3.3 Vaccination Strategies Targeting Innate Immunity

Traditional vaccination strategies primarily focus on eliciting adaptive immune responses, particularly the production of neutralizing antibodies and memory T cells. However, recent research highlights the importance of innate immunity in shaping the overall immune response to vaccination. Innovative vaccination strategies are being developed to target and enhance innate immune pathways, providing a more comprehensive and robust protective response (Khader *et al*., 2020) [13]. Adjuvants play a crucial role in this approach. Adjuvants are substances added to vaccines to enhance their immunogenicity by stimulating the innate immune system. Modern adjuvants are designed to activate PRRs and other innate immune receptors, mimicking natural infection and inducing a strong initial immune response. For example, the adjuvant AS01, used in the malaria vaccine RTS,S, activates TLR4, leading to enhanced production of cytokines and a more robust adaptive immune response. Similarly, cyclic dinucleotides as adjuvants have shown promise in activating the STING pathway, a critical component of the innate immune response to viral DNA (Rameshbabu, Labadie, Argulian, & Patnaik, 2021) [20].

Furthermore, live-attenuated vaccines and viral vectors can stimulate innate immune pathways more effectively than traditional inactivated or subunit vaccines. These vaccines contain replication-competent viruses that activate PRRs and induce various immune responses. For example, the recombinant vesicular stomatitis virus (rVSV) vector used in the Ebola vaccine activates multiple PRRs, leading to a strong and rapid innate immune response supporting adaptive immunity development (Patel, Delgado, & Nasr, 2020) [19].

3.4 Integrating Advances for Enhanced Immunity

The integration of these advancements offers a multifaceted approach to enhancing innate immunity. Combining immunomodulatory drugs with genetic or epigenetic modifications can provide a synergistic effect, boosting the overall immune response to viral infections. For instance, combining TLR agonists with CRISPR-Cas9 mediated enhancement of PRR expression can lead to a more potent and sustained antiviral response. Additionally, incorporating novel adjuvants into vaccine formulations can enhance innate and adaptive immune responses, providing comprehensive protection against viral pathogens (Brezgin *et al*., 2021) [4].

Despite the promise of these advancements, several challenges remain. The potential for overstimulation of the immune system and subsequent tissue damage necessitates careful regulation and balance of immune activation. Understanding the long-term effects of genetic and epigenetic modifications is crucial to ensure safety and efficacy. Continued research is essential to refine these strategies and develop safe and effective interventions that enhance innate immunity without adverse effects.

In conclusion, recent advances in immunomodulatory drugs, genetic and epigenetic modifications, and vaccination strategies offer promising avenues for enhancing innate immunity. These approaches can provide rapid and broad-spectrum protection against viral infections, complementing traditional adaptive immune responses. As our understanding of the innate immune system deepens, these advancements hold the potential to revolutionize antiviral therapies and improve public health outcomes.

4. Challenges and Limitations in Enhancing Innate Immunity

Enhancing innate immunity to combat viral infections represents a promising frontier in medical research, yet it has challenges and limitations. Addressing these complexities is crucial for developing safe and effective therapies that harness the innate immune system's potential while mitigating potential risks.

4.1 Potential Side Effects and Safety Concerns

One of the primary concerns in enhancing innate immunity is the potential for adverse side effects and safety issues. Immunomodulatory drugs and interventions that boost innate immune responses may inadvertently lead to excessive inflammation, tissue damage, or autoimmune reactions. For example, systemic administration of cytokines, such as interferons, can cause flu-like symptoms, fatigue, and gastrointestinal disturbances. Moreover, prolonged activation of innate immune pathways may contribute to chronic inflammatory conditions, posing long-term health risks.

Similarly, genetic and epigenetic modifications aimed at enhancing innate immune functions must be carefully evaluated for safety. Off-target effects of gene editing technologies like CRISPR-Cas9 could inadvertently disrupt normal cellular functions or lead to unintended genetic mutations. While reversible in principle, epigenetic modifications may have unpredictable consequences on immune cell function and overall health. Therefore, rigorous preclinical and clinical studies are essential to assess the safety profile of these interventions before widespread clinical application (Brezgin *et al*., 2021) [4].

4.2 Balancing Immune Activation and Regulation

Achieving a delicate balance between immune activation and regulation is another significant challenge in enhancing innate immunity. While robust immune activation is necessary to effectively combat viral infections, excessive or dysregulated immune responses can be detrimental. Overactivation of inflammatory pathways may lead to cytokine storms, where uncontrolled release of cytokines causes systemic inflammation and multi-organ dysfunction, as observed in severe cases of viral infections like COVID-19 (Nazerian, Ghasemi, Yassaghi, Nazerian, & Hashemi, 2022) [18].

Moreover, chronic activation of innate immune responses can disrupt immune homeostasis and impair the body's ability to mount effective responses against subsequent infections. Immune exhaustion, characterized by decreased responsiveness to stimuli, may result from prolonged or repeated activation of innate immune pathways. Therefore, strategies that modulate rather than amplify innate immune responses may offer a more balanced approach to enhancing antiviral defenses.

4.3 Resistance and Viral Evasion Mechanisms

Viruses have evolved sophisticated mechanisms to evade and subvert the host's innate immune defenses, posing a significant challenge to therapeutic interventions to enhance innate immunity. For instance, viruses may encode proteins that inhibit PRR signaling or interfere with the production and function of interferons and cytokines. Additionally, viruses can manipulate host cellular machinery to prevent recognition and clearance by immune cells.Furthermore, viral mutations, particularly in RNA viruses with high mutation rates, can lead to the emergence of viral variants that evade immune detection or neutralization. This phenomenon is exemplified by the evolution of SARS-CoV-2 variants, such as Delta and Omicron, which exhibit enhanced transmissibility and potential immune evasion properties. These viral adaptations underscore the need for flexible and adaptable therapeutic strategies that effectively target diverse viral strains and variants (Khandia *et al*., 2022; Zhang *et al*., 2024) [14, 31].

4.4 Technological and Clinical Challenges

From a technological perspective, developing effective therapies that target innate immunity requires a deep understanding of immune system dynamics and the specific mechanisms involved in antiviral responses. Innovations in drug delivery systems, such as nanoparticle-based carriers or targeted delivery platforms, are needed to ensure precise and effective delivery of immunomodulatory agents to the site of infection or immune cells.Clinically, translating laboratory discoveries into safe and efficacious treatments poses logistical and regulatory challenges. Therapeutic interventions must be tested in preclinical models and human clinical trials to establish safety, efficacy, and optimal dosing regimens. Regulatory approval processes ensure that interventions meet stringent standards for patient safety and therapeutic benefit, adding to the timeline and complexity of bringing novel therapies to market.

Addressing these challenges requires a multidisciplinary approach integrating basic research, translational medicine, and clinical trials. Future research should focus on developing targeted therapies that modulate innate immune

responses with precision and specificity, minimizing off-target effects and maximizing therapeutic efficacy. Advances in computational modeling and artificial intelligence may facilitate the prediction of immune reactions and aid in designing personalized treatment strategies tailored to individual patient profiles.Furthermore, combination therapies that synergistically target multiple aspects of innate immunity, such as PRR activation, cytokine modulation, and immune cell recruitment, may enhance therapeutic outcomes while reducing the risk of resistance and adverse effects. Collaborative efforts between academic researchers, pharmaceutical industries, and regulatory agencies are essential to accelerate developing and deploying novel innate immune-based therapies against viral infections.

5. Future Directions and Perspectives

As research into enhancing innate immunity against viral infections advances, several promising directions and perspectives are shaping the field. These include exploring emerging technologies and approaches, the integration of innate immunity with adaptive immunity, and the translational research efforts to bring these innovations into clinical applications.

5.1 Emerging Technologies and Approaches

The future of enhancing innate immunity against viral infections is closely tied to emerging technologies that offer new ways to manipulate and augment immune responses. One area of intense interest is the development of nanotechnology-based delivery systems. Nanoparticles can be engineered to deliver immunomodulatory agents, such as TLR agonists or cytokines, directly to immune cells or infected tissues. These targeted delivery systems enhance the specificity and efficacy of therapeutic interventions while minimizing off-target effects.

Moreover, advancements in gene editing technologies, such as CRISPR-Cas9, hold promise for precisely modulating innate immune responses at the genetic level. Researchers are exploring strategies to enhance the expression of key immune genes or disrupt viral evasion mechanisms using CRISPR-based approaches. These technologies offer unprecedented opportunities to tailor immune responses to individual viral infections and overcome resistance mechanisms.

5.2 Integration with Adaptive Immunity

A key frontier in enhancing innate immunity lies in understanding and harnessing its interactions with adaptive immunity. While innate immunity provides immediate defense against viral pathogens, adaptive immunity offers long-term protection through memory T cells and antibodies. Integrating innate immune activation with adaptive immune responses can amplify antiviral immunity and improve vaccine efficacy.

Recent studies have highlighted the role of innate immune activation in shaping adaptive immune responses to vaccines. Adjuvants that stimulate innate immune pathways, such as TLR agonists or nanoparticle-based carriers, can enhance the immunogenicity of vaccines by promoting antigen presentation and cytokine production. This integration ensures robust activation of innate and adaptive immune components, enhancing protection against viral infections.

5.3 Translational Research and Clinical Applications

Translating basic research findings into clinical applications is critical in realizing the potential of enhanced innate immunity against viral infections. Translational research aims to bridge the gap between laboratory discoveries and patient care by developing and validating novel therapeutic interventions.

Clinical trials are pivotal in evaluating the safety, efficacy, and optimal dosing of immunomodulatory drugs, gene therapies, and vaccine adjuvants targeting innate immunity. Rigorous clinical testing ensures that interventions meet regulatory approval standards and provide patients meaningful benefits. Moreover, real-world applications of these therapies in diverse patient populations help refine treatment protocols and identify potential challenges or adverse effects.

Furthermore, collaborative efforts between academia, industry, and regulatory agencies are essential for advancing translational research in innate immune enhancement. Partnerships facilitate the sharing of resources, expertise, and infrastructure needed to conduct large-scale clinical trials and accelerate the development timeline of novel therapies. Regulatory agencies play a crucial role in evaluating clinical studies' safety and efficacy data, ensuring that innovative therapies meet stringent standards for patient safety and therapeutic benefit.

6. References

1. Abakushina EV, Popova LI, Zamyatnin Jr AA, Werner J, Mikhailovsky NV, Bazhin AV. The advantages and challenges of anticancer dendritic cell vaccines and NK cells in adoptive cell immunotherapy. Vaccines. 2021; 9(11):1363.
2. Barnabei L, Laplantine E, Mbongo W, Rieux-Laucat F, Weil R. NF-κB: At the borders of autoimmunity and inflammation. Frontiers in Immunology. 2021; 12:716469.
3. Behzadi P, García-Perdomo HA, Karpiński TM. Toll‐like receptors: General molecular and structural biology. Journal of Immunology Research. 2021; 2021(1):9914854.
4. Brezgin S, Kostyusheva A, Bayurova E, Volchkova E, Gegechkori V, Gordeychuk I, *et al*. Immunity and viral infections: modulating antiviral response via CRISPR–Cas systems. Viruses. 2021; 13(7):1373.
5. Davis JS, Ferreira D, Paige E, Gedye C, Boyle M. Infectious complications of biological and small molecule targeted immunomodulatory therapies. Clinical Microbiology Reviews. 2020; 33(3). Doi: 10.1128/cmr. 00035-00019.
6. Diaz-Arévalo D, Zeng M. Nanoparticle-based vaccines: Opportunities and limitations. In Nanopharmaceuticals (pp. 135-150): Elsevier, 2020.
7. Díaz-Dinamarca DA, Salazar ML, Castillo BN, Manubens A, Vasquez AE, Salazar F, *et al*. Protein-based adjuvants for vaccines as immunomodulators of the innate and adaptive immune response: Current knowledge, challenges, and future opportunities. Pharmaceutics. 2022; 14(8):1671.
8. Federico S, Pozzetti L, Papa A, Carullo G, Gemma S, Butini S, *et al*. Modulation of the innate immune response by targeting toll-like receptors: A perspective on their agonists and antagonists. Journal of Medicinal

Chemistry. 2020; 63(22):13466-13513.
9. Galli G, Vacher P, Ryffel B, Blanco P, Legembre P. Fas/CD95 signaling pathway in damage-associated molecular pattern (DAMP)-sensing receptors. Cells. 2022; 11(9):1438.
10. Goraya MU, Zaighum F, Sajjad N, Anjum FR, Sakhawat I, ur Rahman S. Web of interferon stimulated antiviral factors to control the influenza A viruses replication. Microbial pathogenesis. 2020; 139:103919.
11. Hamrashdi MA, Brady G. Regulation of IRF3 activation in human antiviral signaling pathways. Biochemical Pharmacology. 2022; 200:115026.
12. Hogg SJ, Beavis PA, Dawson MA, Johnstone RW. Targeting the epigenetic regulation of antitumour immunity. Nature reviews Drug discovery. 2020; 19(11):776-800.
13. Khader SA, Divangahi M, Hanekom W, Hill PC, Maeurer M, Makar KW, *et al*. Targeting innate immunity for tuberculosis vaccination. The Journal of clinical investigation. 2020; 129(9):3482-3491.
14. Khandia R, Singhal S, Alqahtani T, Kamal MA, Nahed A, Nainu F, *et al*. Emergence of SARS-CoV-2 Omicron (B. 1.1. 529) variant, salient features, high global health concerns and strategies to counter it amid ongoing COVID-19 pandemic. Environmental research. 2022; 209:112816.
15. Lapenta C, Gabriele L, Santini SM. IFN-alpha-mediated differentiation of dendritic cells for cancer immunotherapy: Advances and perspectives. Vaccines. 2020; 8(4):617.
16. Li D, Wu M. Pattern recognition receptors in health and diseases. Signal transduction and targeted therapy. 2021; 6(1):291.
17. McDaniel MM, Meibers HE, Pasare C. Innate control of adaptive immunity and adaptive instruction of innate immunity: Bi-directional flow of information. Current opinion in immunology. 2021; 73:25-33.
18. Nazerian Y, Ghasemi M, Yassaghi Y, Nazerian A, Hashemi SM. Role of SARS-CoV-2-induced cytokine storm in multi-organ failure: Molecular pathways and potential therapeutic options. International Immunopharmacology. 2022; 113:109428.
19. Patel D, Delgado E, Nasr P. Ebola Virus Disease: The Biology, Pathology, Treatments, and Advancements. Kean Quest. 2020; 3(1):6.
20. Rameshbabu S, Labadie BW, Argulian A, Patnaik A. Targeting innate immunity in cancer therapy. Vaccines. 2021; 9(2):138.
21. Rehwinkel J, Gack MU. RIG-I-like receptors: Their regulation and roles in RNA sensing. Nature Reviews Immunology. 2020; 20(9):537-551.
22. Sepulveda-Crespo D, Resino S, Martinez I. Innate immune response against hepatitis C virus: Targets for vaccine adjuvants. Vaccines. 2020; 8(2):313.
23. Sharma SK, Gupta OP, Pathaw N, Sharma D, Maibam A, Sharma P, *et al*. CRISPR-Cas-led revolution in diagnosis and management of emerging plant viruses: New avenues toward food and nutritional security. Frontiers in Nutrition. 2021; 8:751512.
24. Sun S, Barreiro LB. The epigenetically-encoded memory of the innate immune system. Current opinion in immunology. 2020; 65:7-13.
25. Tan SYX, Zhang J, Tee W-W. Epigenetic regulation of inflammatory signaling and inflammation-induced cancer. Frontiers in Cell and Developmental Biology. 2022; 10:931493.
26. Tanaka K, Heil M. Damage-associated molecular patterns (DAMPs) in plant innate immunity: Applying the danger model and evolutionary perspectives. Annual review of phytopathology. 2021; 59(1):53-75.
27. Tien F-M, Lu H-H, Lin S-Y, Tsai H-C. Epigenetic remodeling of the immune landscape in cancer: therapeutic hurdles and opportunities. Journal of Biomedical Science. 2023; 30(1):3.
28. Vercammen E, Staal J, Beyaert R. Sensing of viral infection and activation of innate immunity by toll-like receptor 3. Clinical microbiology reviews. 2008; 21(1):13-25.
29. Wicherska-Pawłowska K, Wróbel T, Rybka J. Toll-like receptors (TLRs), NOD-like receptors (NLRs), and RIG-I-like receptors (RLRs) in innate immunity. TLRs, NLRs, and RLRs ligands as immunotherapeutic agents for hematopoietic diseases. International Journal of Molecular Sciences. 2021; 22(24):13397.
30. Xu Y-D, Cheng M, Shang P-P, Yang Y-Q. Role of IL-6 in dendritic cell functions. Journal of Leukocyte Biology. 2022; 111(3):695-709.
31. Zhang H, Liu Y, Liu Z. Nanomedicine approaches against SARS-CoV-2 and variants. Journal of Controlled Release. 2024; 365:101-111.